| 查看: 3887 | 回复: 17 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
农产品中农药监测的免疫传感器的疑问
已经有0人回复
-
纳米传感器监测农药残留的疑惑
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有293人回复
-
如何高效的测量腺病毒的粒径和电位
已经有0人回复
-
谁有人卫版 《毒理学基础》第七版书籍
已经有0人回复
-
26有没有老师想收做定量药理的学生啊
已经有3人回复
-
26在职申博—生物与医药—抗体/ADC药物方向，江浙沪，有项目，可带资。
已经有1人回复
-
26考博申请 学or专
已经有15人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
医学超声影像负责人招聘-中国科学院赣江创新研究院
+1/977
-
西湖大学拓扑光学、非厄米光学、太赫兹方向博士后招聘
+2/238
-
坐标广州，征女友
+2/58
-
海南大学海洋技术与装备学院-科研助理招聘（可读博）膜分离水处理方向
+1/38
-
有没有人做过这种结构的顺式体向反式体的转化？
+1/33
-
澳大利亚麦考瑞大学(Macquarie University)国际博士硕士全额奖学金-计算机-26年中开学
+1/32
-
同济大学脑机智能团队脑机接口方向招生招聘
+1/29
-
上海交通大学-宁波东方理工大学联合培养博士生 – 力学
+1/17
-
【青岛大学】2026年生物与医药申请考核制博士生招生（含少数民族骨干人才）
+1/10
-
德国图宾根大学诚招岗位制博士（地下流固化学反应耦合模拟方向）
+1/10
-
墨尔本大学(QS13)招全奖博士、CSC资助博士/访问学者(生物医学材料/器官芯片等方向)
+1/9
-
上海大学生物有机电子材料及器件团队博士研究生招聘
+1/9
-
中北大学冯瑞教授*开山大弟子*招募
+1/8
-
中国地质大学（武汉）杨华明课题组刘磊研究员招收冶金固废资源高值化利用方向博士
+1/8
-
哈工大（深圳）国家级青年人才 钟颖教授课题组 新增26级博士名额！欢迎报名！
+1/5
-
墨尔本大学(QS13)急招CSC博士(补齐全奖)/访问学者/博士后(生物医学材料/器官芯片)
+1/5
-
香港中文大学（深圳）陈筱萌 课题组招生公告（博士 / 博后 / 硕士 / RA）
+1/4
-
澳科大药学院诚招2026年秋季药剂学/生物材料硕士研究生（2026年3月5日报名截止）
+1/4
-
国内树枝状聚合物现在进入量产了吗？
+1/3
-
苏州大学国家级青年人才团队2026年博士招生（有机光电功能材料方向）
+1/2
11楼2013-04-06 12:19:13
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35